Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210288 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2EGFRGAA | |
| SCHEMBL210447 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2EGFRGAA | |
| SCHEMBL2554483 | 0.73 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2EGFRHSD17B10 | |
| SCHEMBL16152464 | 0.72 | CHRM2 (0.42) | ALDH1A1KDM4ESMN1; SMN2EGFRTSHR | |
| SCHEMBL2759473 | 0.72 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2EGFRHSD17B10 | |
| SCHEMBL13270161 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2EGFR | |
| SCHEMBL17833337 | 0.70 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL13821478 | 0.68 | KDM4E (0.40) | ALDH1A1KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL15330725 | 0.67 | L3MBTL1 (0.50) | ALDH1A1KDM4ESMN1; SMN2EGFRHSD17B10 | |
| SCHEMBL12630133 | 0.66 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | ALDH1A1 3015/4885KDM4E 587/4885SMN1; SMN2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.